Unlocking Low-Dose, Long-Duration Expression with Fully Modified saRNA to Transform Vaccine & Therapeutic Performance
- Drive potent, durable protein expression at low doses by using modified nucleotides that preserve saRNA activity and maximize translational efficiency
- Suppress innate immune activation to improve tolerability and dosing flexibility, enabling safer multi-dose regimens and expanding therapeutic use cases
- Combine chemical modification, RdRp engineering, and optimized multi-gene architectures to achieve optimal saRNA performance